Zika vaccine development - current progress and challenges for the future
Zika virus is an emergent pathogen that gained significant importance during the epidemic in South and Central America as unusual and alarming complications of infection were recognized. Although initially considered a self-limited benign infection, a panoply of neurologic complications were recogni...
Saved in:
Published in: | Tropical medicine and infectious disease Vol. 4; no. 3; pp. 1 - 9 |
---|---|
Main Author: | |
Format: | Journal Article |
Language: | English |
Published: |
Switzerland
MDPI
14-07-2019
MDPI AG |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Zika virus is an emergent pathogen that gained significant importance during the epidemic in South and Central America as unusual and alarming complications of infection were recognized. Although initially considered a self-limited benign infection, a panoply of neurologic complications were recognized including a Guillain-Barre-like syndrome and in-utero fetal infection causing microcephaly, blindness, and other congenital neurologic complications. Numerous Zika virus vaccines were developed, with nine different vaccines representing five different platforms entered into clinical trials, one progressing to Phase II. Here we review the current landscape and challenges confronting Zika virus vaccine development. |
---|---|
Bibliography: | Tropical Medicine and Infectious Disease, Vol. 4, No. 3, Sep 2019: 1-9 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Disclaimer: Joel N. Maslow is an employee of GeneOne Life Science, a developer of a Zika vaccine. |
ISSN: | 2414-6366 2414-6366 |
DOI: | 10.3390/tropicalmed4030104 |